Product image of Icatibant Hikma (Icatibant) supplied by GNH India

Icatibant Hikma

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Hikma (Icatibant)

Icatibant, the active ingredient in Icatibant Hikma, is a bradykinin B2 receptor antagonist presented as a subcutaneous solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid reduction of swelling. The drug works by competitively blocking the bradykinin B2 receptor, thereby preventing the vasodilation and increased vascular permeability that cause edema.

GNH India supplies Icatibant Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway.

  • Hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of acute swelling attacks.
  • Hereditary angioedema (type I and II): shortens the duration of facial and peripheral edema.
  • Hereditary angioedema abdominal attacks: reduces pain and gastrointestinal swelling associated with an episode.

How It Works

  • Icatibant is a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks the action of bradykinin, a peptide that induces vasodilation and increases vascular permeability. The inhibition prevents the cascade that leads to fluid extravasation and tissue swelling, thereby mitigating the acute manifestations of hereditary angioedema.

Side Effects

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling at injection site: localized erythema or edema.
  • Nausea: transient gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Dizziness: temporary sensation of light‑headedness.
  • Fatigue: feeling of tiredness after administration.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Angioedema of the throat or airway: potentially life‑threatening swelling.
  • Severe hypotension: marked drop in blood pressure.
  • Thrombocytopenia: low platelet count observed in rare cases.
  • Stevens‑Johnson syndrome: severe skin reaction, extremely rare.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: unknown safety; weigh benefits against possible infant exposure.
  • Renal impairment: use with caution; monitor renal function.
  • Concomitant ACE inhibitors or ARBs: may increase bradykinin levels; observe for enhanced edema.
  • Known hypersensitivity: discontinue immediately if severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medicines that affect the bradykinin system or vascular tone.

Major Interactions (Avoid)

  • ACE inhibitors: may raise bradykinin levels and increase risk of angioedema.
  • Angiotensin II receptor blockers (ARBs): similar potential to augment bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing contraceptives: may influence HAE severity; monitor clinical response.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): can exacerbate swelling; observe for increased attacks.
  • Other bradykinin antagonists: additive blockade may increase adverse effects; adjust therapy as needed.

Frequently Asked Questions

Icatibant Hikma is used to treat acute attacks of hereditary angioedema (HAE) in patients who have a deficiency of C1‑inhibitor. By rapidly reducing swelling, it helps relieve symptoms in the face, extremities, abdomen, and airway that can occur during an HAE episode.

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The dosing regimen for Icatibant is determined by the prescribing healthcare professional. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, and a second dose may be given if the attack does not improve within a specified time frame.

Safety of Icatibant in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified clinician.

To order Icatibant Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative to Icatibant is plasma‑derived or recombinant C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant directly blocks bradykinin receptors, offering a rapid, non‑protein‑based approach, whereas C1‑inhibitor therapy restores the missing inhibitor. Choice depends on patient response, availability, and clinical considerations.

Icatibant should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period.

Icatibant is given as a subcutaneous injection, usually into the abdomen or thigh. The injection is performed using a prefilled syringe or autoinjector, and patients are instructed to rotate injection sites to minimize local reactions.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, airway‑compromising angioedema, and marked hypotension. Patients should be monitored closely after the first dose, and any signs of severe allergic reaction require immediate medical attention.

Icatibant should not be used by individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is advised in patients with severe renal impairment, pregnant or breastfeeding women, and those taking medications that increase bradykinin levels, such as ACE inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT